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G3+ GU toxicity was observed in 1% of DE-EBRT and 2.5 % of 
LDR-PB arms. No acute G3+ GI toxicity was observed. The 
cumulative incidence of late G3+ GU toxicity at 2 and 6 years 
was 4% and 8% in DE-EBRT versus 8% and 18% LDR-PB 
respectively (p<0.0001). Urethral strictures requiring 
dilatation, urinary retention requiring a TURP or TUIP, and 
severe urinary incontinence were the most common G3+ GU 
events and were all significantly less common with DE-EBRT 
at 1%, 1% and 0% compared to LDR-PB at 7.5%, 3%, and 2.5%. 
The prevalence of G3+ GU toxicity at 2 and 6 years with DE-
EBRT was 1.6% and 1.1% versus 5.4% and 4.7% with LDR-PB. 
The cumulative incidence of late G3+ GI toxicity at 2 and 6 
years was 3% and 4% with DE-EBRT versus 3% and 9% with 
LDR-PB respectively (p=0.07). Grade 3 rectal bleeding and 
fecal incontinence were observed in 3.5% and 0% of DE-EBRT 
patients versus 3.0% and 1.5% with LDR-PB. The prevalence of 
G3+ GI toxicity at 2 and 6 years with DE-EBRT was 2% and 0% 
versus 1.0% and 0% with LDR-PB. 
 
Conclusions: GI toxicity did not differ significantly between 
arms, but the cumulative incidence of late G3+ GU toxicity 
was 18% with LDR-PB versus 8% with DE-EBRT. Since many 
toxicity events were temporary and others were reversed or 
ameliorated by urologic procedures, the long term 
prevalence of G3+ GU toxicity with LDR-PB is much lower 
than the incidence rate. 
*ASCENDE-RT- Androgen Suppression Combined with Elective 
Nodal and Dose Escalated Radiation Therapy is an NCI 
registered trial (NCT00175396). 
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Purpose/Objective: Modern diagnostic imaging gives high-
resolution anatomical detail enabling detection of tumour 
deposits measuring only a few millimetres. As a consequence, 
it is plausible that the occult tumour-load in what we 
currently identify as the 'elective volume' is much less than 
before. Therefore, dose reduction to elective lymph node 
regions is increasingly becoming a topic of interest in 
radiation therapy (RT) for head and neck cancer, in order to 
reduce acute and late radiation sequelae. The aim of this 
study is to provide insight in patterns of recurrence in 
electively irradiated lymph node regions after intensity-
modulated radiation therapy (IMRT) for head and neck 
cancer. 
Materials and Methods: A total of 264 patients having stage 
cT2-4N0-2M0 squamous cell carcinoma of the oropharynx, larynx 
or hypopharynx treated with curative intent using 
accelerated IMRT between 2008-2011 were included. 
Excluded were patients treated with surgery or 
chemotherapy. Median follow-up is 2.7 years. RT planning 
CT-scans from all patients were reviewed and all lymph 
nodes (short -axis diameter ≥5mm and ≤10mm) localized in 
the elective volume were identified and delineated. For each 
node, we measured volume, long- and short-axis diameter. 
The exact sites of regional recurrences were reconstructed 
and projected on the initial RT treatment planning CT-scan 
by performing co-registration with diagnostic imaging of the 
recurrence. 
Results: Actuarial rate of recurrence in electively irradiated 
lymph node regions was 5.1% (95% CI:2.4-7.8%) at 2 years.  
On the RT planning CT-scans, 1166 electively irradiated 
lymph nodes (short -axis diameter ≥5mm and ≤10mm) were 
identified. Volumetric analysis showed an increased risk of 
recurrence with increasing nodal volume, up to 19.4% (95% 
CI:5.1-33.7%) at 3 years for lymph nodes >1.5cc. The summed 
long- and short-axis diameter showed to be a pragmatic 
alternative for the more laborious volume calculations, 
having an optimal combination of sensitivity (88%) and 
specificity (79%) when setting the cut-off to ≥17mm (figure 
1). 
 
 
 
Figure 1: Recurrence in electively irradiated lymph nodes 
according to summed short- and long-axis diameter 
Univariate analysis: <17mm versus ≥17mm (p<0.001)  
Conclusions: This is the first study focussing on recurrences 
in electively irradiated lymph nodes in a large and 
homogeneous population after definitive IMRT. Important 
risk-factors were identified that can help clinicians in the 
pre-treatment risk-assessment of borderline-sized lymph 
nodes. Not overtly pathologic lymph nodes having a summed 
diameter ≥17mm may require an intermediate RT dose. For 
low-risk elective areas (all nodes <17mm), de-escalation 
below the traditional 50Gy can be considered.  
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Purpose/Objective: Here we report the prospectively 
documented short- and long-term health-related quality of 
life (HRQoL) of a large cohort of patients with advanced 
laryngeal cancer. The patients were treated in a randomized 
trial comparing accelerated radiotherapy with carbogen and 
nicotinamide (ARCON) against accelerated radiotherapy alone 
(AR). 
Materials and Methods: Of 345 patients with cT2-4 laryngeal 
cancer, 174 were randomly assigned to AR and 171 to ARCON. 
HRQoL was assessed using the European Organisation for 
Research and Treatment of Cancer (EORTC) QoL 
Questionnaire-C30 (QLQ-C30) and the Head&Neck cancer 
module (QLQ-H&N35) at baseline, at completion of 
radiotherapy and at 6, 12, and 24 months post-baseline. 
Tumor- and patient related factors with potential impact on 
quality of speech and swallowing were analyzed separately. 
Data were analyzed two years after inclusion of the last 
patient. 
Results: Compliance with completion of questionnaires at 
different time-points was high (AR: 60-79%; ARCON 70-81%). 
Significant clinical impact (>10 effect-points) was observed 
for nearly all items of the QLQ-C30 and QLQ-H&N35 between 
baseline and end of treatment. At 6 months, scores returned 
to baseline level for all items with exception of dry mouth, 
sticky saliva, taste- and smell perception. No difference in 
HRQoL score between AR and ARCON was observed at any of 
the time points. The rate of patients reporting 'quite a bit' or 
'very much' complaints of dry mouth, sticky saliva, or changes 
in taste- and smell perception for AR vs ARCON is limited to 
26% vs 33%, 20% vs 23% and 20% vs 17% at 2 years, 
respectively. At 2 years from diagnosis, the majority of 
patients treated by AR vs ARCON, have 'not at all' or 'a little' 
complaints of swallowing (77% vs 81%; P=.37) or speech (64 vs 
63%, P=.51). Long-term function of speech and swallowing for 
patients presenting with T4 tumors was not impaired 
compared to T2-T3 tumors. The use of a feeding tube at 2 
years from diagnosis was limited to 6% vs 4% of AR vs ARCON 
patients, respectively. 
Conclusions: With ARCON, a high local control (± 80%) and a 
significantly improved regional control rate are observed 
while maintaining excellent speech and swallowing function 
for the majority of patients, independent of T-stage. Long 
term dry mouth, sticky saliva and changes in taste and smell 
perception are limited to one quarter of patients and not 
different between both treatment arms. 
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Purpose/Objective: To determine the predictors and 
patterns of regional recurrence in patients treated with 
stereotactic body radiotherapy (SBRT) for primary lung 
cancers. 
Materials and Methods: Patients with primary lung cancer 
treated with SBRT were identified from a multi-institutional 
(5) database of 965 cases. Patients with previous lung cancer 
or multiple lung tumors (231) were excluded leaving 734 
analyzable patients. Details of patient factors, treatment 
specifics, toxicity and clinical outcomes were extracted from 
the database. All events were calculated from the end of 
radiotherapy. Estimates of local (LR), regional (RR), and 
distant recurrence (DR) were calculated using the competing 
risk method. Cause specific (CSS) and overall survival (OS) 
were calculated using the Kaplan-Meier method. Details of 
locations and number of simultaneous regional failures were 
categorized by lymph node (LN) anatomic level. 
Results: The median follow-up time was 1.4 years (0.1-14.8 
years). The median age was 76 years (42-94), 367(50%) were 
male, 644 (88%) tumors were peripheral per RTOG 0236 and 
43 (6%) had mediastinal staging with EBUS/mediastinoscopy. 
Tumor location was right upper lobe (RUL) 235 (32%), right 
middle lobe (RML) 52 (7%), right lower lobe (RLL) 86 (12%), 
left upper lobe (LUL) 260 (35%), left lower lobe (LLL) 79 (11%) 
and missing 21 (3%). All patients had a staging PET scan. The 
median maximum tumor dimension was 2.3cm (0.7- 8.5cm). 
476 had pathological proven cancer. The median RT dose was 
54 Gy (18-64) and the median number of fractions was 3 (1-
10). There were 64 RR. The 2 and 5 year recurrence rates 
were LR 5.6% and 8.3%, RR 9.0% and 13.4%, and DR 14.6% and 
19.0% respectively. On univariable analysis (UVA) tumor 
dimension (p=0.3), tumor baseline SUV (p=0.1), histology 
(p=0.3), RT dose (p=0.5), tumor location (p=0.8) and gender 
(p=0.6) were not correlated with RR. On the biopsy proven 
cohort (n=476) the 2 and 5 year recurrence rates were LR 
7.6% and 11.0%, RR 9.5% and 12.9%, and DR 17.9% and 21.5% 
respectively. On UVA tumor baseline SUV (p=0.03) was 
correlated with RR. There were 181 simultaneous sites of RR. 
16 patients had single station RR in station 12R (1RUL), 
station 10R (2RUL, 2RLL), station 10L (1LLL), station 7 (2RUL, 
2RLL, 1 LLL), station 4R (1RUL, 1RLL), station 2R (1RUL) and 
station 5 (1LLL). The pattern of LN failure was station 10 
n=23 (13%), station 7 n=70 (39%), station 4 n=25 (14%), 
station 2 n=10 (6%) and other stations n=53 (29%). The most 
common RR levels were stations 4 & 7 for RUL and LUL, 
stations 4, 5, 7 & 10 for LLL tumors and stations 7&10 for RML 
and RLL tumors. 
Conclusions: Baseline SUV is correlated with RR. Stations 10, 
7 and 4 were most common stations for RR. These patterns of 
recurrence may guide nodal staging procedures prior to SBRT.  
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